IPHARMA was authorized to conduct the Phase III clinical trial of Levopront®
On June 22, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase III clinical study of the medicinal product Levopront® (levodropropizine).
Protocol № LDP0114 "Multicenter open-label randomized clinical trial of the efficacy and safety of Levopront®syrup 30 mg/5 ml in comparison with Libexin® 100 mg tablets in patients suffering from dry non-productive cough caused by acute upper respiratory infection".
A total of 15 centers in 6 cities of Russia will be involved in the study conduct.
The study objective: To assess the efficacy and safety of Levopront® in comparison with Libexin® in patients suffering from dry non-productive cough caused by acute upper respiratory infection.
In conduct of the study IPHARMA specialists will manage monitoring, data collecting and processing, medical expertise and study report preparation in accordance with international standards.